Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-862-7037175
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings DateN/A
OptionableNot Optionable
Arno Therapeutics (OTCMKTS:ARNI) Frequently Asked Questions
What is Arno Therapeutics' stock symbol?
Arno Therapeutics trades on the OTCMKTS under the ticker symbol "ARNI."
Has Arno Therapeutics been receiving favorable news coverage?
Media stories about ARNI stock have been trending neutral on Saturday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arno Therapeutics earned a news impact score of 0.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Arno Therapeutics.
Who are some of Arno Therapeutics' key competitors?
Some companies that are related to Arno Therapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ), Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP) and Eastgate Biotech (ETBI).
What other stocks do shareholders of Arno Therapeutics own?
Who are Arno Therapeutics' key executives?
Arno Therapeutics' management team includes the folowing people:
- Mr. David M. Tanen J.D., Sec. & Director (Age 48)
How do I buy shares of Arno Therapeutics?
Shares of ARNI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arno Therapeutics' stock price today?
One share of ARNI stock can currently be purchased for approximately $0.0016.
What is Arno Therapeutics' official website?
How can I contact Arno Therapeutics?
Arno Therapeutics' mailing address is 200 State Route 31 Ste 104, FLEMINGTON, NJ 08822-5812, United States. The company can be reached via phone at +1-862-7037175.
MarketBeat Community Rating for Arno Therapeutics (OTCMKTS ARNI)
MarketBeat's community ratings are surveys of what our community members think about Arno Therapeutics and other stocks. Vote "Outperform" if you believe ARNI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNI will underperform the S&P 500 over the long term. You may vote once every thirty days.
